久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Richmond-based E. Claiborne Robins Co. Inc. lawsuit against Teva Pharmaceutical seeks $110 million

firstwordpharmaDecember 02, 2018

Tag: lawsuit , Teva Pharmaceutical , E. Claiborne Robins , lawsuit

  • Former specialty drug company E. Claiborne Robins has filed a $110-million lawsuit suit against Teva in a dispute over a 2007 asset purchasing agreement, reported Richmond.com.

  • The lawsuit accuses Teva of failing to live up to "commercially reasonable efforts" to market a patented muscle relaxer called Amrix developed by Robins and sold in 2007 to Cephalon, which Teva went on to acquire in 2011.

  • The suit alleges that under an agreement formula, Teva must pay Robins $97.5 million, and with interest added, the amount rises to at least $110 million.

Previous:Medicines for Europe Welcomes Competitiveness Council Discussion to Stop Delocalisation of Medicines Manufacturing. It is Time to Effectively Position Europe as a Global Hub for the Production of Medicines

Next:FDA Could Improve Designation Review Consistency; Rare Disease Drug Development Challenges Continue

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service